2011
DOI: 10.4137/cmrt.s1644
|View full text |Cite
|
Sign up to set email alerts
|

Almotriptan: Review of Efficacy in Treating Migraine in Adolescents

Abstract: Migraine is a common disabling neurological disorder, often starting in children and adolescents. Triptans, a class of selective 5HT1b/d receptor agonists, have been shown to be effective and well-tolerated as acute therapy in adult migraineurs. Data examining efficacy and tolerability of triptans in adolescents are limited compared with adults. Almotriptan has recently been approved by the USA regulatory authorities (FDA) for the acute treatment of migraine headache in adolescent patients (age 12 to 17 years)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 47 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?